{"id":"NCT00842348","sponsor":"Ipsen","briefTitle":"Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour","officialTitle":"Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2009-02-12","resultsPosted":"2017-02-17","lastUpdate":"2022-10-12"},"enrollment":89,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non Functioning Entero-pancreatic Endocrine Tumour"],"interventions":[{"type":"DRUG","name":"lanreotide (Autogel formulation)","otherNames":["Lanreotide","Lanreotide Autogel","Somatuline","Somatuline Autogel","Somatuline Depot"]}],"arms":[{"label":"Lanreotide (Autogel formulation)","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT00353496).","primaryOutcome":{"measure":"Adverse Events","timeFrame":"Throughout the study until the completion/early discontinuation visit.","effectByArm":[{"arm":"Lanreotide Autogel","deltaMin":40,"sd":null},{"arm":"Placebo","deltaMin":46,"sd":null},{"arm":"Total","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","Belgium","Czechia","France","Italy","Poland","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":["26743120","33052555"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":42},"commonTop":["Diarrhoea","Abdominal pain","Cholelithiasis","Nausea","Vomiting"]}}